Provided by Tiger Trade Technology Pte. Ltd.

Whitehawk Therapeutics, Inc.

4.73
-0.1000-2.07%
Post-market: 4.730.00000.00%19:30 EDT
Volume:226.21K
Turnover:1.07M
Market Cap:269.65M
PE:-4.25
High:4.94
Open:4.87
Low:4.64
Close:4.83
52wk High:5.50
52wk Low:1.68
Shares:57.01M
Float Shares:28.74M
Volume Ratio:0.82
T/O Rate:0.79%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.1137
EPS(LYR):-0.3328
ROE:-44.98%
ROA:-28.70%
PB:1.47
PE(LYR):-14.21

Loading ...

Whitehawk Therapeutics Inc expected to post a loss of 9 cents a share - Earnings Preview

Reuters
·
May 05

Whitehawk Therapeutics announces annual shareholder meeting

Reuters
·
Apr 29

Whitehawk Therapeutics' Antibody Drug Conjugates Indicate Potential Efficacy Against Cancer, Oppenheimer Says

MT Newswires Live
·
Apr 21

Oppenheimer Sticks to Their Buy Rating for Whitehawk Therapeutics (WHWK)

TIPRANKS
·
Apr 21

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Whitehawk Therapeutics (WHWK), COMPASS Pathways (CMPS) and Monopar Therapeutics Inc (MNPR)

TIPRANKS
·
Apr 21

Whitehawk Therapeutics publishes HWK-016 preclinical presentation on MUC16-targeting ADC

Reuters
·
Apr 20

Whitehawk announces presentation of new preclinical data across ADC portfolio

TIPRANKS
·
Apr 20

Whitehawk says Phase 1 trial for HWK-016 ADC in ovarian, endometrial cancers ongoing

Reuters
·
Apr 20

Whitehawk Therapeutics CEO joins Jones Trading Post-AACR virtual fireside chat

Reuters
·
Apr 17

Whitehawk Therapeutics publishes ovarian cancer MUC16 expression study presentation

Reuters
·
Apr 13

Trade Alert: President Of Whitehawk Therapeutics David Lennon Has Sold Stock

Simply Wall St.
·
Apr 11

Whitehawk Therapeutics presents analysis of MUC16 at SGO

TIPRANKS
·
Apr 10

Whitehawk says Phase 1 trial tests MUC16-targeted ADC HWK-016 in gynecologic cancers

Reuters
·
Apr 10

JonesTrading Sticks to Their Buy Rating for Whitehawk Therapeutics (WHWK)

TIPRANKS
·
Apr 07

Whitehawk Therapeutics to present three preclinical ADC abstracts at AACR Annual Meeting 2026

Reuters
·
Mar 18

Whitehawk Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
Mar 17

Whitehawk Therapeutics Inc expected to post a loss of 6 cents a share - Earnings Preview

Reuters
·
Mar 13

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Rapid Micro Biosystems (RPID), Lexicon Pharmaceuticals (LXRX) and Whitehawk Therapeutics (WHWK)

TIPRANKS
·
Mar 13

Whitehawk Therapeutics reports bigger-than-expected Q4 loss on higher R&D costs

Reuters
·
Mar 12

Whitehawk Therapeutics FY2025 net loss fell 68% to USD 20.6 million

Reuters
·
Mar 12